Mustafa Kemal Çelen

Mustafa Kemal Çelen

Auto-generated profile, based on publicly available information

Mustafa Kemal Çelen

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Dicle University, Diyarbakır, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2026 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
YÇYeliz Çiçek
Yeliz Çiçek
SKSafak Kaya
Safak Kaya
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen
SBSEYİT ALİ BÜYÜKTUNA
SEYİT ALİ BÜYÜKTUNA
MÇMehmet Çelik
Mehmet Çelik
EYErcan Yenilmez
Ercan Yenilmez
Background: Socioeconomic disadvantage may influence the chronic hepatitis B (CHB) care continuum and the stage at which clinically relevant liver disease is recognised. However, evidence linking both individual- and area-level socioeconomic disadvantage to histologically assessed liver fibrosis in CHB remains limited. We examined whether socioeconomic disadvantage at the individual and area levels was associated with liver fibrosis severity in adults with CHB in Türkiye. Methods: In this nationwide multicentre observational study, adults with CHB who underwent liver biopsy in routine care between 1 January 2019 and 31 December 2024 across 24 centres in Türkiye were screened. Clinical and histopathological data were obtained retrospectively from medical records, while socioeconomic data were collected after biopsy through structured face-to-face interviews. Fibrosis was staged using the Ishak system. Individual socioeconomic indicators and province-level categories of the socioeconomic development index (SEDI) were examined. The primary analysis used ordinal logistic regression. Supportive analyses included multivariable logistic regression, 1:1 propensity score matching with conditional logistic regression, overlap weighting, likelihood-ratio tests for interaction, chi-square or Fisher’s exact tests, Kruskal–Wallis tests, and Wilcoxon rank-sum tests, with Benjamini–Hochberg adjustment for post-hoc comparisons. Results: The analytic cohort included 956 adults, of whom 53.7% were male. Mild fibrosis (Ishak 0–2) was present in 73.1%, moderate fibrosis (3–4) in 21.7%, and advanced fibrosis/cirrhosis (5–6) in 5.2%. In multivariable ordinal regression, higher fibrosis stage was associated with older age at biopsy (adjusted OR = 1.12 per 10-year increase, 95% CI : 1.02–1.24; P = 0.019), longer travel time to a centre capable of CHB follow-up (adjusted OR = 1.53 per category, 95% CI : 1.30–1.79; P < 0.001), longer duration of residence in the current place of residence (adjusted OR = 1.21 per 5-year increase, 95% CI : 1.03–1.42; P = 0.023), and lower residential socioeconomic development (adjusted OR = 1.97 per one-level decrease, 95% CI : 1.82–2.15; P < 0.001). In matched and overlap-weighted comparisons of SEDI 6 versus SEDI 1, the corresponding estimates were OR = 26.00 (95% CI : 8.21–82.37; P < 0.001) and OR = 24.75 (95% CI : 8.96–68.36; P < 0.001), respectively. Conclusions: Liver fibrosis severity in adults with CHB was associated more consistently with area-level socioeconomic disadvantage of the current place of residence than with birthplace socioeconomic context or most individual socioeconomic indicators. These findings support a social epidemiological interpretation in which place-based disadvantage may be more closely linked to fibrosis severity at clinical presentation, potentially through unequal access to timely follow-up and specialist assessment.

1 January 2021 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
YYYeşim Yıldız
Yeşim Yıldız
YDYakup Demir
Yakup Demir
MÖMeryem Merve Ören
Meryem Merve Ören
ÖKÖmer Karaşahin
Ömer Karaşahin
IKIrem Akdemir Kalkan
Irem Akdemir Kalkan
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen

30 May 2026 in Scientific Reports
Verified
Journal Article
Open access
YÇYeliz Çiçek
Yeliz Çiçek
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen
HPHüsnü Pullukçu
Hüsnü Pullukçu
SBSEYİT ALİ BÜYÜKTUNA
SEYİT ALİ BÜYÜKTUNA
FCFatma Kesmez Can
Fatma Kesmez Can
YTYeşim Taşova
Yeşim Taşova
To quantify the prevalence of HIV testing indications among hospitalised adults in Türkiye, assess HIV testing coverage when clinically indicated, and identify missed diagnostic opportunities in a national multicentre point-prevalence survey. We conducted a national multicentre cross-sectional point-prevalence survey across tertiary referral hospitals from all seven geographical regions of Türkiye. Adult inpatients present at 08:00 on a predefined index day were assessed for predefined HIV testing indications, including AIDS-defining conditions, indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and conditions in which unrecognised HIV could substantially affect clinical management. Among 3,425 hospitalised adults without known HIV infection, 699 (20.4%) had at least one documented HIV testing indication. HIV testing was requested by the primary clinical team in 424/699 patients (60.7%). Testing was lowest in patients with indicator conditions associated with an expected undiagnosed HIV prevalence ≥ 0.1%, and these conditions were independently associated with higher odds of non-performance of HIV testing by the primary clinical team than AIDS-defining conditions (corresponding adjusted odds ratio [aOR] 3.05, 95% confidence interval [CI] 1.67–5.81). In centres with a specialised HIV outpatient clinic, the odds of non-performance of HIV testing by the primary clinical team were independently lower among patients with an appropriate testing indication (corresponding aOR 0.64, 95% CI 0.43–0.95). Following study-team facilitation, overall testing coverage increased to 677/699 (96.9%). Three reactive screening results were identified, including two confirmed new HIV diagnoses. HIV testing indications were common among hospitalised adults in Türkiye, but non-performance of HIV testing by the primary clinical team remained frequent, particularly for non-AIDS indicator conditions. Strengthening indicator-condition-guided testing through structured clinical pathways and institutional HIV expertise may reduce non-performance and support earlier HIV diagnosis.

28 September 2022 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
ÇMÇiğdem Mermutluoğlu
Çiğdem Mermutluoğlu
MBMuhammed Bekçibaşı
Muhammed Bekçibaşı
ÖDÖzcan Deveci
Özcan Deveci
SCSerkan Cerrah
Serkan Cerrah
İKİbrahim Kaplan
İbrahim Kaplan
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen